Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Allison Betof Warner, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the long-term outcomes and responses to retreatment in melanoma patients who responded to PD-1 inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.